FILE – In this March 13, 2012 file photo, Indian pharmacologist removes mice from cages to study the reaction of cytotoxic drugs, inside a containment facility of the Research and Devel

 

              FILE – In this March 13, 2012 file photo, Indian pharmacologist removes mice from cages to study the reaction of cytotoxic drugs, inside a containment facility of the Research and Devel
FILE – In this March 13, 2012 file photo, Indian pharmacologist removes mice from cages to study the reaction of cytotoxic drugs, inside a containment facility of the Research and Development Centre of Natco Pharma Ltd., in Hyderabad, India. India's patent appeals office has Monday, March 4, 2013, rejected international drug maker Bayer AG's plea to stop Indian company Natco Pharma Ltd. from manufacturing a cheaper generic version of a patented cancer drug. Bayer Corp., a subsidiary of the German pharma giant in Pittsburgh, Pennsylvania, markets sorefinib as Nexavar for about $5,600. Natco's version would cost Indian patients $175 a month. (AP Photo/Mahesh Kumar A., File)